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Abstract
Background: To simplify clinical scale lymphocyte expansions, we investigated the use of the WAVE®, a closed
system bioreactor that utilizes active perfusion to generate high cell numbers in minimal volumes.
Methods: We have developed an optimized rapid expansion protocol for the WAVE bioreactor that produces
clinically relevant numbers of cells for our adoptive cell transfer clinical protocols.
Results: TIL and genetically modified PBL were rapidly expanded to clinically relevant scales in both static bags
and the WAVE bioreactor. Both bioreactors produced comparable numbers of cells; however the cultures
generated in the WAVE bioreactor had a higher percentage of CD4+ cells and had a less activated phenotype.
Conclusions: The WAVE bioreactor simplifies the process of rapidly expanding tumor reactive lymphocytes under
GMP conditions, and provides an alternate approach to cell generation for ACT protocols.
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Background
Metastatic melanoma is a highly aggressive cancer with a
5 year survival rate of less than 10% [1]. The FDA cur-
rently approves three treatments for metastatic melanoma,
dacarbazine [2]), interleukin-2 [3], and ipilimumab [4].
Dacarbazine has an objective response rate of 10-15% with
few, if any, durable remissions [2]. IL-2 has an objective
response rate of about 15%, with a complete response of
less than 5% [2,5]. In a large randomized trial with ipilimu-
mab, the objective response rate was reported to be about
10%, with 0.6% complete responses [4]. Inhibitors of domi-
nant BRAF mutations are currently in large, randomized
clinical trials, and could be approved in the near future
[6]. Phase II studies with these agents did not result in a
durable complete response for most patients and so addi-
tional approaches to treating advanced melanoma are
required.
In light of this, the development of adoptive cell trans-
fer (ACT) therapy using autologous tumor infiltrating
lymphocytes (TIL) or peripheral blood lymphocytes
(PBL) modified to express specific T cell receptors target-
ing tumor antigens, holds great promise [7]. The adoptive
transfer of TIL combined with a lymphodepleting pre-
conditioning regimen can yield objective responses in 48-
70% of metastatic melanoma patients, with up to 40% of
patients experiencing a durable complete response [8-10].
It is not always possible to generate a TIL culture from
every resected tumor and for most tumor histologies there
are few, if any, TIL that are able to recognize autologous
tumor in vitro. To increase the range of tumors that can
be treated by this approach, it is possible to genetically
engineer peripheral T cells to express T cell receptors or
chimeric antigen receptors that target specific tumor anti-
gens [11]. A recent report described the use of NY-ESO-1
transduced PBL following lymphodepletion [12]. Five of
11 patients with advanced refractory melanoma demon-
strated objective clinical responses to treatment, and four
of six patients with refractory synovial sarcoma exhibited
objective tumor regression. Objective clinical responses
with genetically retargeted lymphocytes have also been
reported in lymphoma and colorectal carcinoma [13,14].
These adoptive transfer therapies rely on the large scale
ex vivo activation and expansion of TIL or genetically
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modified PBL generating an average of about 5 × 1010
cells for reinfusion into patients. Traditionally this has
been achieved by static culture methods. In our facility,
the final “rapid expansion protocol” (REP) phase of cell
expansion requires two weeks of culture and is initiated
in multiple T175 flasks. After sufficient expansion cells
are transferred to 3 liter gas permeable bags. Up to 24
bags are required, along with frequent culture manipula-
tions for accurate counting, and to allow episodic batch
feeding and bag splitting for maintenance of cell densities
in the optimal cell concentration range (0.5-1.5 × 106
cells per ml), while diluting waste products such as
ammonia and lactate. The semi-open system coupled
with frequent culture manipulations introduces multiple
opportunities for contamination, thus, highly skilled per-
sonnel are required. In addition the final cell product
volume can be as high as 50 liters, which requires specia-
lized equipment, disposables, dedicated space and sub-
stantial harvest time. These technical challenges have
proved an impediment to a wider dissemination of ACT.
We and others have investigated alternate systems for
lymphocyte expansion for individualized patient therapies.
An improved TIL expansion process would optimally be
simplified, “closed,” capable of producing the desired num-
ber of cells in a minimal volume, and affordable. In this
paper we investigate the use of the WAVE bioreactor, a
system that utilizes continuous media exchange, to rapidly
expand tumor infiltrating lymphocytes and genetically
modified PBL under GMP conditions for clinical trials.
Our studies demonstrate the WAVE system is capable of
generating TIL and PBL gene modified cells with compar-
able properties to 3 liter gas permeable static bags. Cellular
and immunological analysis suggests that the WAVE bior-
eactor may be a preferred method of cell expansion for
some cell subsets or phenotypes.
Methods
Patient material, tumor cell lines, and retroviral vectors
All excised tumor tissue and peripheral blood products
were collected as part of approved clinical protocols
(Clinical Research Center Institutional Review Board
approved) and all patients gave their signed informed
consent.
Tumor cell lines 624mel (HLA-A2+) and 888mel (HLA-
A2-), and the TAP deficient cell line T2 were maintained
in RPMI1640 supplemented with 10% heat inactivated calf
serum (Hyclone, Logan UT), 12 mM L-glutamine, 25 mM
HEPES, 55 μM b-mercaptoethanol, 100 units/ml penicil-
lin, 100 μg/ml streptomycin, and 10 μg/ml gentamicin.
g-retroviral vectors used to transduce patient PBL were
manufactured for ongoing clinical trials in accordance
with current good manufacturing practices by the Indi-
ana University Vector Production Facility or the Surgery
Branch Vector Production Facility. T cell receptors
(TCR) used in this study targeted one of the following
epitopes (all restricted by HLA-A2): NY-ESO-1:157-165,
MART-1:27-35, or gp100:154-162.
Initiation of young TIL and genetically modified
peripheral blood lymphocytes
Young TIL cultures were generated as previously
described [15-17]. Briefly, homogenous cell suspensions
were established from excised tumors using overnight
enzymatic digestion or by a GentleMACS dissociator
(Miltenyi Biotec). Cell number and viability were deter-
mined by trypan blue staining and counting on a Neu-
bauer hemocytometer. The cell suspensions were plated
in 24 well plates at a concentration of 0.5 × 106 cells
per ml in RPMI1640 supplemented with 10% heat inac-
tivated human AB serum, 12 mM L-glutamine, 25 mM
HEPES, 55 μM b-mercaptoethanol, 100 units/ml penicil-
lin, 100 μg/ml streptomycin, 10 μg/ml gentamicin, and
6000 IU/ml IL-2. The cells were incubated at 37°C with
5% CO2. On day 5 after initiation of the TIL culture
half the media was replaced with fresh media. Media
was then exchanged and confluent wells were split every
2-3 days, and when a sufficient number of cells were
obtained, all wells were pooled and rapid expansions
were initiated. Some young TIL underwent CD8+
enrichment using GMP quality immunomagnetic beads
(Miltenyi) as previously described prior to rapid
expansion.
Patients PBL were transduced as previously described
[12,18,19]. Briefly, BPL obtained by apheresis were, puri-
fied over a ficoll-Hypaque cushion and stimulated with
50 ng/ml anti-CD3 (OKT3) and 300 IU/ml IL-2 in AIM V
supplemented with 5% heat inactivated human AB serum.
After 2 days the cells were harvested, washed, and trans-
duced by plating in 6-well plates that were pre-coated
with retrovirus and Retronectin®. The cells were incubated
at 37°C overnight, and then transferred to a second set of
plates for a second transduction. After overnight incuba-
tion, the transduced PBMC were washed, resuspended,
and maintained at 0.5-2 x106 cells per ml in AIM V media
supplemented with 5% heat inactivated human AB serum
plus 300 IU/ml IL-2.
Initiation of rapid expansion protocol (REP)
The REP was initiated in T175 flasks for the first seven
days as previously described. Briefly, TIL (1 × 106) or
transduced PBL (2 × 106) were mixed with a 200 or 100
fold excess (respectively) of irradiated (40 Gy) feeder
cells, 30 ng/ml OKT3 anti-CD3 antibody, and 3000 IU/
ml IL-2 in 150 ml media. Five days later, about 2/3 of
the media was removed by aspiration and replaced with
fresh media containing 3000 IU/ml IL-2. Two days later,
on day 7 of the REP, cells were transferred from flasks
to an alternate growth chamber as described below.
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Rapid expansion using gas permeable static bags
On day 7 of the REP, the cells and 300 ml media from two
T175 flasks were transferred to a 3 liter Baxter LifeCell
culture bag, and an equal volume of media (AIM V sup-
plemented with 5% human serum plus 3000 IU/ml IL-2)
was added. Bags were sampled and the cell concentration
was determined daily. The bags were fed as required to
maintain a cell density of approximately 0.5-1.5 × 106
cells/ml. Each patient’s cells were initially fed with up to
10 liters of AIM V supplemented with 5% human AB
serum and 3000 IU/ml IL-2. Subsequent AIM V (without
serum) supplemented with 3000 IU/ml of IL-2 was used
to feed cells. Cell products, including TIL and TCR trans-
duced PBL, with a target number at infusion of 5 × 1010
cells would start from 36-48 T175 flasks and have a final
process volume at the conclusion of the REP (day 14) of
30 - 50 liters.
Rapid expansion using the WAVE bioreactor
On day 7 of the REP a 10 liter Cellbag was attached to the
tray of a WAVE bioreactor 2/10 system. The Cellbag was
inflated with 5% CO2 and the system was tared. A bag of
medium and a 20 liter bag to collect waste were attached
to the appropriate ports of the Cellbag. Media was added
to the cell bag to a final volume of 1.5 liters. The media
was warmed to 37°C and aerated by rocking at 7 rpm at
an angle of 6° for 2 hours. TIL or genetically modified PBL
were introduced to the CellBag by gravity feed and the
volume was made to 3 liters. Media was perfused in 50 ml
increments using a semicontinuous program. Samples
were sterilely drawn daily from the needleless ports for
determination of cell number, lactate, and glucose concen-
trations. The glucose concentration in the cell bag was
measured using an Accu-Chek hand held blood glucose
monitor and test strips. Lactate levels were measured
using the Lactate Pro™ blood lactate test meter from Ark-
ray (Kyoto, Japan). Perfusion rates were varied daily to
maintain a media glucose concentration of approximately
170 mg/dl. Initially cells were perfused with AIM V sup-
plemented with 5% human AB serum, 0.02% Pluronic, and
3000 IU/ml IL-2 (10 liters), after the initial 10 liters of
media were expended cells were perfused with AIM V
(without serum) supplemented with 0.02% Pluronic and
3000 IU/ml of IL-2. All media bags were maintained at
4°C in the dark to reduce degradation of components.
Safety, functional, and phenotypic analysis
Cell products were tested for contamination with myco-
plasma, fungi and aerobic or anaerobic bacteria by the
Clinical Center hospital Clinical Laboratory Improvement
Amendments (CLIA)-approved microbiology laboratories.
Endotoxin was quantified using the FDA approved Pyro-
gent 5000 kinetic turbidimetric assay from Lonza. Quanti-
fication of tumor cell contamination in expanded TIL
cultures was performed using HMB45 and anti-MART-1
antibodies with a validated assay in the Clinical Center
Department of Cytopthology.
The expression of the following cell surface markers on
TIL and genetically modified PBL expanded in LifeCell
bags and the WAVE bioreactor were compared by 6 color
flow cytometry on a Canto II Flow cytometer: CD3, CD4,
CD8, CD56, CD45RA, CD45RO, CD62L, CCR7, CD25,
CD27, CD28 (BD Biosciences), In addition, for the geneti-
cally modified PBL, the expression of the introduced TCR
was analyzed by staining with the cognate tetramer com-
plex (Beckman).
Antigen specific cytokine secretion by TCR transduced
PBL was measured as previously described [17]. Briefly,
genetically modified PBL were incubated with HLA-
matched or HLA-mismatched melanoma cell lines or T2
cells pulsed with cognate or non-specific peptides over-
night at 37°C, and the IFN-g concentration of coculture
supernatants was quantified by an enzyme linked immu-
nosorbent assay. A positive signal was defined as twice the
amount of IFN-g released by the relevant negative control
well(s) and at least 200 pg/ml.
Statistical analysis
All data was analyzed using the statistical analysis tools in
Excel, including Student’s T-Test and Paired T-Test as
indicated in the text. Results are expressed as the mean ±
the standard error.
Results
Active perfusion of the WAVE bioreactor creates A stable
culture environment
We wanted to determine if the culture environment of
lymphocytes rapidly expanded in the WAVE bioreactor,
with its active perfusion of media, was more stable than
that of lymphocytes undergoing rapid expansion in static
bags with an episodic feeding regimen. Patients’ cells were
simultaneously rapidly expanded in static bags and the
WAVE bioreactor and the glucose and lactate concentra-
tion, and pH of the media was monitored daily throughout
the duration of the expansion. The concentration of glu-
cose and lactate, and the pH of the media was measured
prior to adding the cells to the two bioreactors on day 7.
Figure 1 shows the data from a representative expansion.
The glucose concentration showed the greatest degree of
variation between the two bioreactors, with the WAVE
bioreactor stabilizing at about 150 mg/dl within two days
of inoculation and perfusion initiation, while the glucose
concentration in static bags peaked with each addition of
media before undergoing a gradual decline (Figure 1a).
The lactate level (Figure 1b) stabilized at approximately 11
mmol/l within 24 hours of cell addition and perfusion
initiation in the WAVE bioreactor, while the static bags
took longer to stabilize. By the end of the rapid expansion
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the lactate levels in both bioreactors converged. The pH in
both bioreactors fluctuated within a narrow range (Figure
1c); however the degree of fluctuation was smaller in the
WAVE bioreactor. In comparison to the static culture
bags, the WAVE bioreactor and its active perfusion of
media creates a more stable culture environment through-
out the duration of the rapid expansion.
Clinical scale rapid expansions of TIL and genetically
modified PBL can be achieved in the WAVE bioreactor
TIL and genetically modified PBL can be rapidly
expanded in the WAVE bioreactor to clinically useful
numbers. Patients either had their TIL expanded solely
in the Static bags (n = 25) or solely in the WAVE bior-
eactor (n = 27). The mean of total cell numbers har-
vested from static bags was 4.5 × 1010 (± 5.1 × 109) and
4.4 × 1010 (± 4.9 × 109) for WAVE bioreactor (Figure
2a). This corresponds to a mean fold expansion of 1259
(± 137) and 1130 (± 127) for static bags and the WAVE
bioreactor respectively (Figure 2b). There was no statis-
tical difference in the fold expansions achieved in the
two bioreactors. The viability of TIL expanded in static
bags and the WAVE bioreactor was also similar, 96.95%
and 95.26% respectively (p = 0.07). We were concerned
that differences in the ability of the bioreactors to
expand cells maybe masked by the fact we were analyz-
ing different populations of cells.
To address this interpopulation variation we took indi-
vidual patients (n = 26) and simultaneously expanded
some of their cells in static bags and some of their cells
in the WAVE bioreactor to determine if comparable
numbers of cells and fold expansions could be achieved

































































Figure 1 The Wave bioreactor creates a more stable culture
environment for rapidly expanding lymphocytes. A comparison
of media depletion for a culture grown in static bags (circles) or the































































Figure 2 The WAVE bioreactor and static bags expand T
lymphocytes comparably. A comparison of TIL expanded in either
static bags (n = 25, circles) or the WAVE bioreactor (n = 27,
triangles). a) Total TIL number expanded b) Fold expansion.
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when analyzing the same populations of cells (Figure 3a).
The overall fold expansion of patients’ TIL was indepen-
dent of the bioreactor used for expansion (paired T-Test,
p = 0.9), with a mean fold expansion of 1281 (± 100) and
1295 (± 128) for static bags and the WAVE bioreactor
respectively. TIL expanded from WAVE bioreactors were
also active in mediating tumor regressions in patients. 25
patients received TIL expanded in the WAVE bioreactor,
of which 6 had a reduction in the diameter of their evalu-
able lesions of greater than 30%.
Similarly, the WAVE bioreactor was able to expand
NY-ESO, MART-1 and gp-100 TCR transduced periph-
eral blood mononuclear cells (n = 10) to clinically useful
levels. Each patient’s transduced PBL were simulta-
neously expanded in static bags and the WAVE bioreac-
tor. There was no significant difference in the overall fold
expansion of genetically modified PBL in static bags or
the WAVE bioreactor (444 ± 74 and 502 ± 76, p = 0.13)
(Figure 3c). Therefore, use of the WAVE bioreactor as
the sole bioreactor for cell expansion would yield the
same number of TIL and genetically modified PBL as
would growth in static bags.
Wave bioreactor expanded, TCR transduced lymphocytes
have A higher apparent avidity than bag expanded
lymphocytes
Successful adoptive transfer treatments rely on the gen-
eration of large quantities of functionally active cells.
For this reason, we assessed the functionality of cells
that had under gone concurrent rapid expansions in sta-
tic bags and the WAVE bioreactor (Table 1). TCR trans-
duced PBL rapidly expanded in the WAVE bioreactor
secreted more IFN-g in response to 0.1, 0.01 and 0.001
μm of cognate peptide pulsed on to T2 cells, when com-
pared with cells expanded in static bags. This observa-
tion of increased IFN-g release was independent of the
TCR specificity, suggesting that WAVE bioreactor
expanded cells have a higher apparent avidity for their
cognate peptide. When TCR transduced PBL from the
two bioreactors were cocultured with HLA matched and
mismatched melanoma cell lines, comparable amounts
of IFN-g were secreted, indicating that the apparent
higher avidity of WAVE bioreactor expanded cells did
not translate into enhanced tumor recognition.
The phenotype of TIL and genetically modified PBL
expanded in static bags and the WAVE bioreactor differ
To determine whether the cellular composition of TIL
expanded under conditions of constant perfusion would
differ from TIL expanded using static bags, the differentia-
tion status of patients’ TIL simultaneously expanded in
both bioreactors was determined by FACS analysis. The
following cell surface markers were evaluated, CD3, CD4,
CD8, CD56, CD45RA, CD45RO, CD62L, CCR7, CD27 and
CD28 (Figures 4 and 5). Expansion in either static bags or
the WAVE bioreactor did not affect the percentage of
CD3+ positive TIL or genetically modified PBL (Figure 3a
and 3d). Overall WAVE bioreactor expanded TIL had a
lower proportion of CD8 positive cells (Figure 4c) and a
higher proportion of CD4 positive cells (Figure 4b) than
concurrent expansions in static bags (p = 0.005 and p =
0.02 respectively). Interestingly, genetically modified PBL
rapidly expanded in the WAVE bioreactor also had a sig-
nificantly lower percentage of CD8+ cells and a signifi-
cantly higher percentage of CD4+ cells compared to the
expansions carried out in static bags (p = 0.03 and p = 0.02
respectively) (Figure 4e,f). The percentage of CD8 + cells
that were tetramer positive between the WAVE bioreactor
and static bags appears to decrease, although this does not
reach statistical significance. This probably is due to the
Figure 3 The WAVE bioreactor and static bags expand the
same lymphocyte cultures comparably. a) A comparison of the
fold expansion of TIL that underwent concurrent rapid expansion in
static bags (circles) and the WAVE bioreactor (triangles). b) A
comparison of the fold expansion of genetically modified PBL that
underwent concurrent rapid expansion in static bags (circles) and
the WAVE bioreactor (triangles).
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relatively small sample size (Figure 4h). The WAVE bior-
eactor had a lower percentage of tetramer + CD4+ cells
compared to the static bags, suggesting that the WAVE
bioreactor preferentially expanded populations of untrans-
duced cells (Figure 4g).
Phenotypic analysis revealed a higher percentage of
CD8+CD28+ and CD8+CD62L+ cells (Figures 5a,b) in
the WAVE bioreactor than in static bags (p = 0.01, p <
0.01 respectively). In contrast, the percentage of both
CD4+ and CD8+ positive TCR transduced cells that
Table 1 A table of IFN-g secretion in response to HLA matched and mismatched cell lines and to T2 cell pulsed with
peptide recognized by the transduced TCR
Melanoma Cell Lines T2 cells pulsed with peptide (μM/ml)
938 624 Irrelevant Peptide Specific Peptide
TCR Bioreactor A2- A2+ 1.0 1.0 0.1 0.01 0.001 0.0001
NY-ESO Patient 1 Static Bags 40 19300 44 > 126650 45600 5095 1080 136
Wave 68 46950 128 > 182100 83200 23350 2770 646
Patient 2 Static Bags 345 39700 694 > 241000 52250 4195 985 339
Wave 410 40700 1876 > 219650 58400 8650 2374 1302
Patient 3 Static Bags 79 > 31250 84 > 84800 23850 2425 242 40
Wave 78 > 30150 120 > 83000 31500 4830 534 139
Patient 4 Static Bags 16 4725 27 11045 1075 166 45 29
Wave 18 5770 43 12445 1610 236 54 33
Patient 5 Static Bags 7 11780 855 > 113300 25555 2635 1346 14
Wave 1201 16140 147 > 125300 63400 8230 469 177
Patient 6 Static Bags 129 3505 105 9535 1080 147 40 12
Wave 36 4000 99 26950 2560 315 118 80
Patient 7 Static Bags 23 6565 40 24750 3445 818 393 159
Wave 78 3550 290 > 45100 6240 911 441 204
MART-1 Patient 8 Static Bags 98 > 77225 160 > 58200 11480 1375 544 NA
Wave 148 91625 547 62200 20875 3630 1510 NA
Patient 9 Static Bags 12 66500 30 > 180600 93700 370 490 NA
Wave 65 > 162700 197 > 260700 > 154600 3000 2897 NA
gp154 Patient 10 Static Bags 18 32950 22 NA 4360 2600 739 479





































































































































































































































































Figure 4 The WAVE bioreactor produces cultures with greater numbers of CD4+ cells than static bags. The cell surface expression profile
of TIL a) CD3 b) CD4 c) CD8 and genetically modified PBL d) CD3 e) CD4 f) CD8 g) CD4 and Tetramer h) CD8 Tetramer in static bags (circles)
and the WAVE bioreactor (triangles).
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were also CD27+ was decreased in WAVE bioreactor
expanded cells (p = 0.01 and p = 0.02)(Figure 5c, d)
while in the CD8+ fraction there was a slight increase in
the percentage of CD45RA + cells (data not shown). All
other markers that were analyzed, CD3, CD45RO, CCR7
and CD28, did not vary in a statistically significant man-
ner between the two bioreactors.
Discussion
Initial experiments were performed to optimize the start-
ing cell number, seeding density, day of WAVE bioreactor
inoculation and rocking speed. Static bags and the WAVE
bioreactor expanded TIL and genetically modified PBL
comparably in terms of total cell number, overall fold
expansion and viability. Both bioreactors produce cells
free of bacterial and fungal contamination, with levels of
endotoxin that met or exceeded the requirements of the
certificate of analysis. The composition of the final cell
product differed between the two bioreactors with the
WAVE bioreactor producing a cell product with a higher
percentage of CD4+ cells and a lower percentage of CD8+
cells. In addition to differences in the cellular composition
of final product there were also differences in the activa-
tion status of the cells produced in the two bioreactors,
with WAVE bioreactor expanded TIL cultures having a
higher percentage of CD8+ CD28+ and CD8+ CD62L
positive cells compared to static bag cultures. Genetically
modified PBL expanded in the WAVE bioreactor, in con-
trast, had a lower percentage of CD27+ cells in both the
CD4+ and CD8+ compartments than cultures expanded
in static bags. The functionality of genetically modified
PBL expanded in the two bioreactors was tested in cocul-
ture experiments. When cocultures were performed on T2















































































Figure 5 The WAVE bioreactor and static bags produce cultures with a different phenotypic composition. A comparison of TIL activation
status by cell surface expression of a) CD8 and CD28 b) CD8 and CD62L and genetically modified PBL activation status by cell surface expression
of c) CD4 CD27 d) CD8 CD27 in static bags (circles) and the WAVE bioreactor (triangles).
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TCR, WAVE bioreactor expanded genetically modified
PBL secreted more IFN-g (P < 0.05) at three of the peptide
concentrations tested. Genetically modified PBL expanded
in the two bioreactors were also cocultured with HLA
matched and mismatched melanoma cell lines and there
was no difference in the amount of IFN-g secreted. In an
ongoing clinical trial both WAVE bioreactor expanded
and static bag expanded TIL were able to mediate a signif-
icant shrinkage in the tumor volume of a subset of
patients; however due to the short follow up period the
durability of these responses cannot be assessed.
TIL have been successfully expanded in several styles
of bioreactor, including stirred bioreactors [20], hollow
fiber bioreactors [21,22], a single pass closed system
bioreactor from Aastrom Biosciences [23] as well as in
the WAVE bioreactor [24]. Many bioreactors suffer
from problems of scalability, having an upper volume
limit that prevents the generation of clinically useful cell
numbers with a single unit. The WAVE is a closed sys-
tem bioreactor that has been used extensively in the
manufacture of biologics under cGMP compliant condi-
tions [25,26]. The major advantages of the WAVE bior-
eactor include the small footprint, and the ability to
sample the expansion in real time to monitor cell
growth and bioreactor conditions. The constant perfu-
sion of media in to the WAVE bioreactor prevents the
accumulation of waste products, such as ammonia and
lactate, while maintaining the glucose and glutamine
levels in an optimal range, allowing TIL/PBL cultures to
grow in a reduced volume of culture media at high den-
sities. The reduced volume of patients’ cultures greatly
expedites the downstream processing prior to infusion,
allowing multiple cell products to be harvested per day,
using standard blood bank cell processing equipment.
The total number of culture manipulations is reduced
when expansions are carried out in the WAVE bioreac-
tor, reducing the opportunity for inadvertent operator
culture contamination. The closed nature of this system
also reduces the requirement for large amounts of clean
room space, as media changes can be performed by ster-
ile welding media bags on to the bioreactor.
It is clear that the number and durability of clinical
responses is impacted by composition/quality of the
infused cell product. Previously, Bessar et al noted that
melanoma patients who responded to adoptively trans-
ferred TIL, received greater absolute numbers of CD8+
cells than non responders enrolled on the same trial
[27]. CD8+ cells are the effector cell type responsible for
tumor cell destruction and in vitro, highly activated
CD8+ effector memory cells are the most potent media-
tors of tumor cell lysis. In mice, the most effective cells
upon adoptive transfer are not the most highly activated
CD8+ effector memory cell, but a less activated central
memory cell type and this appears to relate to the ability
of this cell type to persist in the host post transfer
[28,29]. Successful treatment with TIL and genetically
modified PBL relies on lymphodepletion prior to adop-
tive transfer, which is believed to reduce endogenous
competitors for homeostatic cytokines [30]. Upon trans-
fer cells enter a lymphopenic environment that is
enriched for homeostatic cytokines; the less activated
central memory like cells express higher levels of recep-
tors for these cytokines than effector memory like cells,
and this coupled with their lower rate of apoptosis and
higher proliferative potential results in increased
engraftment and persistence.
Due to the fact that CD8+ effector cells are our desired
cell population the increased representation of CD4+
cells in rapid expansions carried out in the WAVE bior-
eactor compared to static bags is problematic. The
underlying cause of this skewed expansion could relate to
differences in the culture microenvironment generated in
the two styles of bioreactor. In static bags the cells rest
on the lower surface of the bag and there is minimal mix-
ing of the bag contents. In this situation there is extensive
cell to cell contact and any secreted factors essential to
cell expansion will exist as gradients, with the highest
concentration surrounding the cells. Contrast this with
the WAVE bioreactor, where the coupling of rocking
with media perfusion creates a more homogenous sus-
pension of cells and oxygenated nutrient rich media. In
this situation any secreted factors will be diluted by the
continual perfusion, while the constant motion will dis-
rupt any gradient formation and reduce the overall time
that cells spend in contact with each other. A second
possibility relates to the need for a surfactant to be pre-
sent in the WAVE bioreactor media to protect cells from
hydrodynamic/shear force damage. When we attempted
to expand TIL in the absence of the surfactant, Pluronic
F68, there was significant cell damage, which resulted in
a reduction in cell viability. In this situation it was neces-
sary to perform a filtration step prior to harvest to
remove the cellular debris, which resulted in further cell
loss and introduced an additional step at which the pro-
duct could become contaminated. To reduce the amount
of cell debris, all TIL and genetically modified PBL had
their WAVE bioreactor expansions performed in the pre-
sence of 0.02% Pluronic F68. In the literature there is
some disagreement as to how non-ionic surfactants such
as Pluronic F68 protect cells. Murhammer and Goochee
[31] have suggested that the pluronic F68 protects by
inserting into and altering the physical properties of the
plasma membrane. This may alter membrane fluidity and
the ability of sensitive cells to respond appropriately in
culture, resulting in the observed skewing of expansion
in favor of CD4+ cells.
The WAVE bioreactor produces fewer overall CD8+
TIL and genetically modified PBL, which may have an
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impact on overall response rates. To date we have only
performed the final 7 days of rapid expansion in the
WAVE bioreactor and it is not clear if this bias would
become more pronounced if cultures are used to inocu-
late the WAVE bioreactor prior to day 7. One solution
to the expansion bias in favor of CD4+ cells is to per-
form CD8+ enrichments on TIL prior to rapid expan-
sion, thus ensuring that higher absolute numbers of
CD8+ are available for patient infusion. Of greater con-
cern is the observation that the WAVE bioreactor pro-
duced a final cell product with fewer transduced CD4+
and CD8+ cells as assessed by tetramer staining than
our standard method using static bags. This suggests
that the WAVE bioreactor is preferentially expanding
untransduced cells, in particular untransduced CD4+
cells. This produces a cell product that has a reduced
representation of cells that are able to specifically target
and lyse tumor cells and one would predict this would
translate in to poorer clinical outcomes.
Because the activation status of transferred cells also
relates to their ability to engraft and clear bulky tumor
masses, we assessed the activation status of TIL and
genetically modified PBL that underwent concurrent
expansion in the WAVE bioreactor and static bags. Cul-
tures that were rapidly expanded in the WAVE bioreac-
tor had a higher percentage of CD8+ CD62L + cells. In
addition, the percentage of CD28 positive cells was also
elevated in WAVE bioreactor expanded cultures, specifi-
cally in the CD8+ cell subset, indicative of these cells
having certain characteristics that are associated with
greater persistence and efficacy upon transfer in murine
models. The WAVE bioreactor therefore appears to be
generating CD8+ TIL with desirable characteristics, and
this could be exploited by only using CD8+ enriched
TIL in rapid expansions to compensate for any preferen-
tial expansion of CD4+ cells. Interestingly, genetically
modified PBL expanded in the WAVE bioreactor have a
more activated phenotype, as indicated by a reduced
percentage of CD27 positive cells, than cells expanded
in static bags. It is unclear why these two cell products
behave differently in the WAVE bioreactor, but, in part,
it may be a reflection of the origin of the cells used to
initiate the expansions. TIL are isolated from a tumor
and are exposed to their cognate antigens. PBL, in con-
trast, will have a higher proportion of naïve cells. If the
WAVE bioreactor is to be used to expand genetically
modified PBL the current conditions will have to be
modified to ensure that the untransduced cells do not
out grow the transduced cells during the rapid expan-
sion. The activation status of these PBL also needs to be
investigated further; generally the down regulation of
CD27 is associated with a more activated phenotype and
a decreased persistence post transfer. For our purposes,
the preferential expansion of CD4+ cells is problematic;
however, for protocols that utilize a CD4+ based cell
product this skewing of expansion could be exploited,
such as in the production of Tregs for the treatment of
conditions, such as Type1 diabetes and for allogenic
transplants [32,33].
We were unable to reliably initiate clinical scale rapid
expansions directly in the WAVE bioreactor. The WAVE
bioreactor was able to achieve high cell densities, in excess
of 1 x107 cells per ml, after an initial 7 day expansion in
T-175 flasks. In a previous report, Sadeghi et al [24] per-
formed concurrent rapid expansions of TILs from 4
donors starting directly in the WAVE bioreactor and static
bags and found similar fold expansions in the two bioreac-
tors (228 and 72 fold expansion in the WAVE and static
bags respectively). However, their reported total fold
expansion was too low to meet our clinical needs. In con-
trast to our findings, they observed no phenotypic or func-
tional variation between the two bioreactors. There are
significant differences in the media compositions and
methodologies used in these two studies, which makes
direct comparison of the results impossible.
There are some disadvantages with the WAVE bioreac-
tor including a difficult transition from research scale
expansions, where the initial cell number and seeding
density are determined, along with the day of WAVE
inoculation and rocking speed, to full scale clinical
expansions. In addition to the WAVE bioreactors them-
selves it is necessary to purchase additional ancillary
equipment. This, along with the inherent complexities of
a system that depends on constant motion, such as a pre-
disposition to electrical and mechanical failure, means
that there is a need for multiple bioreactors to expand a
single patient’s cells. In order to exclusively adopt the
WAVE bioreactor as the sole platform for rapid expan-
sions, therefore requires a substantial initial investment,
which may be beyond the means of a small cell produc-
tion facility that produces only a minimal number of cell
products; however, the WAVE bioreactor is ideal for lar-
ger scale manufacturing facilities, where multiple cell
products need to manufactured concurrently. We have
identified alternative bioreactors which don’t require an
additional expenditure on ancillary equipment, as they
utilize equipment and monitoring systems that are stan-
dard to most cell production facilities [34].
Conclusions
The Surgery Branch of the National Cancer Institute has
had success treating patients with cells expanded in sta-
tic bags and it is clear that cells expanded in this style
of bioreactor can mediate regressions in patients with
advanced, bulky, metastatic melanoma [9]. We have
evaluated the WAVE bioreactor, in an attempt to create
a simplified, GMP compliant clinical expansion protocol.
Differences in the phenotype of cells generated in this
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bioreactor compared to our standard methodology could
impact the frequency or durability of clinical responses,
but these outcomes will need to be evaluated in a clini-
cal trial. The reduction in labor required to maintain
cultures in the WAVE bioreactor, coupled with the
closed nature of this system, suggests that this system
can be a suitable alternative to the static gas permeable
bags.
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